6,150 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Sava Infond d.o.o.

Sava Infond d.o.o. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,150 shares of the medical research company’s stock, valued at approximately $346,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EXAS. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences in the 3rd quarter valued at approximately $34,000. Asset Planning Inc bought a new stake in Exact Sciences in the fourth quarter worth approximately $40,000. Modus Advisors LLC acquired a new position in shares of Exact Sciences during the 4th quarter worth $43,000. AlphaQuest LLC raised its holdings in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 913 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $44.99 on Friday. The firm has a market capitalization of $8.36 billion, a price-to-earnings ratio of -8.08 and a beta of 1.25. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The business has a fifty day simple moving average of $49.87 and a 200 day simple moving average of $57.90. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to analysts’ expectations of $701.45 million. Sell-side analysts expect that Exact Sciences Co. will post -0.58 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on EXAS shares. Benchmark restated a “buy” rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Scotiabank boosted their target price on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Barclays reduced their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Finally, Bank of America lowered their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.83.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.